Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 25 years of experience in analyzing hundreds of companies, especially in Asia. Deep expertise in the following sectors:
- Technology (E-commerce, SaaS, Internet)
- Consumer 
- Special Situations/Deep Value Plays
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

MSCI Std Korea Adds Trading Flow: SK Bioscience, SKIET, & Ecopro BM

SK Chemicals - Its Market Cap Is Only 19% of Its Stake in SK Bioscience

A Major Study in Israel Suggests Natural Immunity Provides 13x Higher Protection than COVID Vaccine

Trading Strategy of SK Bioscience IPO Post Pricing

COVID-19 Vaccinations in Korea: Digging the Details

Event-Driven

End of the Lock-Up Period (6 Months) - The six months lock-up period for the SK Bioscience comes up in one month on September 18th. There are 2.2 million shares that could be sold once the three months lock-up period ends on September 18th, which represents 2.9% of total outstanding shares. <a href="https://www.smartkarma.com/entities/sk-bioscience-co-ltd" target="_blank" data-smartkarma-citation="entities:31484:1" rel="noopener">SK Bioscience (302440 KS)</a> has been one of the best performing stocks in Korea this year. Since its IPO on 18 March 2021, the stock price is up 393%. The stock has especially been very hot in the past month as its stock price is up 103% in this period. Despite the sharp share price appreciation, the six months lockup period is ending in one month. As more investors see the locked up shares potentially coming out into the market, this could cause some negative pressure on the stock. There has been a big re-spread of COVID-19 in South Korea this year. This has been one of the key positive factors impacting SK Bioscience. Unlike many countries that have been able to reduce the number of COVID-19 cases, South Korea has been the reverse with the total number of cases increasing rapidly this year. The number of daily cases of COVID-19 reached all-time high on 11 August when it reached 2,219 cases in South Korea.

End of the Lock-Up Period (6 Months) - The six months lock-up period for the SK Bioscience comes up in one month on September 18th. There are 2.2 million shares that could be sold once the three months lock-up period ends on September 18th, which represents 2.9% of total outstanding shares. SK Bioscience (302440 KS) has been one of the best performing stocks in Korea this year. Since its IPO on 18 March 2021, the stock price is up 393%. The stock has especially been very hot in the past month as its stock price is up 103% in this period. Despite the sharp share price appreciation, the six months lockup period is ending in one month. As more investors see the locked up shares potentially coming out into the market, this could cause some negative pressure on the stock. There has been a big re-spread of COVID-19 in South Korea this year. This has been one of the key positive factors impacting SK Bioscience. Unlike many countries that have been able to reduce the number of COVID-19 cases, South Korea has been the reverse with the total number of cases increasing rapidly this year. The number of daily cases of COVID-19 reached all-time high on 11 August when it reached 2,219 cases in South Korea.

SK Bioscience: Stock Price Up 393% Since IPO & 6 Months Lockup Period Ending in 1 Month